Last reviewed · How we verify
ANG003 Dose A
ANG003 Dose A is an investigational RNA-targeting therapy.
ANG003 Dose A is an investigational RNA-targeting therapy. Used for Investigational treatment for COVID-19.
At a glance
| Generic name | ANG003 Dose A |
|---|---|
| Sponsor | Anagram Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
ANG003 Dose A is an investigational RNA-targeting therapy that targets a specific RNA molecule to modulate gene expression.
Approved indications
- Investigational treatment for COVID-19
Common side effects
- Injection site reactions
Key clinical trials
- Phase 2 Study to Assess the Safety and Efficacy of ANG003 (PHASE2)
- Phase 1 Study to Assess Safety and Efficacy of ANG003 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |